AstraZeneca Statistics

Total Valuation

AstraZeneca has a market cap or net worth of ARS 405.22 trillion. The enterprise value is 440.35 trillion.

Market Cap	405.22T
Enterprise Value	440.35T

Important Dates

The next estimated earnings date is Tuesday, February 10, 2026.

Earnings Date	Feb 10, 2026
Ex-Dividend Date	Aug 8, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.08%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	0.05%
Owned by Institutions (%)	81.24%
Float	1.54B

Valuation Ratios

The trailing PE ratio is 31.46 and the forward PE ratio is 17.93.

PE Ratio	31.46
Forward PE	17.93
PS Ratio	5.09
PB Ratio	6.43
P/TBV Ratio	n/a
P/FCF Ratio	23.36
P/OCF Ratio	19.53
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.84, with an EV/FCF ratio of 25.38.

EV / Earnings	34.19
EV / Sales	5.30
EV / EBITDA	14.84
EV / EBIT	19.37
EV / FCF	25.38

Financial Position

The company has a current ratio of 0.88, with a Debt / Equity ratio of 0.71.

Current Ratio	0.88
Quick Ratio	0.69
Debt / Equity	0.71
Debt / EBITDA	1.57
Debt / FCF	2.58
Interest Coverage	12.24

Financial Efficiency

Return on equity (ROE) is 21.67% and return on invested capital (ROIC) is 13.16%.

Return on Equity (ROE)	21.67%
Return on Assets (ROA)	9.06%
Return on Invested Capital (ROIC)	13.16%
Return on Capital Employed (ROCE)	19.78%
Revenue Per Employee	844.78M
Profits Per Employee	136.60M
Employee Count	94,300
Asset Turnover	0.53
Inventory Turnover	1.59

Taxes

In the past 12 months, AstraZeneca has paid 2.79 trillion in taxes.

Income Tax	2.79T
Effective Tax Rate	17.79%

Stock Price Statistics

The stock price has increased by +84.82% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+84.82%
50-Day Moving Average	64,561.50
200-Day Moving Average	51,127.63
Relative Strength Index (RSI)	52.75
Average Volume (20 Days)	268

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AstraZeneca had revenue of ARS 79.66 trillion and earned 12.88 trillion in profits. Earnings per share was 8,248.60.

Revenue	79.66T
Gross Profit	66.33T
Operating Income	21.80T
Pretax Income	15.68T
Net Income	12.88T
EBITDA	27.98T
EBIT	21.80T
Earnings Per Share (EPS)	8,248.60

Full Income Statement

Balance Sheet

The company has 11.21 trillion in cash and 44.76 trillion in debt, giving a net cash position of -33,548.47 billion.

Cash & Cash Equivalents	11.21T
Total Debt	44.76T
Net Cash	-33,548.47B
Net Cash Per Share	n/a
Equity (Book Value)	63.00T
Book Value Per Share	40,547.71
Working Capital	-5,638.24B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 20.75 trillion and capital expenditures -3,401.58 billion, giving a free cash flow of 17.35 trillion.

Operating Cash Flow	20.75T
Capital Expenditures	-3,401.58B
Free Cash Flow	17.35T
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 83.26%, with operating and profit margins of 27.37% and 16.17%.

Gross Margin	83.26%
Operating Margin	27.37%
Pretax Margin	19.68%
Profit Margin	16.17%
EBITDA Margin	35.12%
EBIT Margin	27.37%
FCF Margin	21.78%

Dividends & Yields

This stock pays an annual dividend of 795.69, which amounts to a dividend yield of 1.16%.

Dividend Per Share	795.69
Dividend Yield	1.16%
Dividend Growth (YoY)	39.02%
Years of Dividend Growth	3
Payout Ratio	52.89%
Buyback Yield	0.08%
Shareholder Yield	1.24%
Earnings Yield	3.18%
FCF Yield	4.28%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AstraZeneca has an Altman Z-Score of 2.98 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.98
Piotroski F-Score	7